Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Imaxio Announces the First Human Clinical Trial Using IMX313 in Tuberculosis

Published: Wednesday, September 04, 2013
Last Updated: Wednesday, September 04, 2013
Bookmark and Share
IMX313, Imaxio’s antigen re-engineering technology, has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial managed by the Jenner Institute at Oxford University.

Imaxio has announced that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

This phase I trial is a dose escalation study that aims to assess the safety and immunogenicity of the tuberculosis vaccine candidate MVA85A-IMX313, a viral vector vaccine encoding the well-known tuberculosis antigen 85A which is fused to Imaxio’s IMX313.

The study will be performed in the UK and led by Prof. Helen McShane from the Jenner Institute at Oxford University.

Imaxio's proprietary antigen re-engineering technology, IMX313, is designed to enhance the immune response and, therefore, the effectiveness of each vaccine in which it is used.

IMX313 brings significant potential as a solution to develop vaccines and immunotherapies for major indications. The technology was designed in response to the challenge in increasing the effectiveness of some human and animal health candidates.

It is currently used for the development of vaccine candidates indicated for influenza, Staphylococcus aureus infection, tuberculosis and malaria.

Tuberculosis remains a significant cause of mortality and morbidity throughout the developing world. Worldwide, there are two million deaths each year from TB. It is estimated that a third of the world’s population is latently infected with Mycobacterium tuberculosis, the bacteria responsible for tuberculosis.

The HIV epidemic and the emergence of multi-drug resistant strains of TB have made the need for improved tuberculosis control even more urgent.

As the currently available vaccine, BCG, is largely ineffective at protecting against adult pulmonary disease in endemic areas, the MVA85A vaccine candidate has been designed to enhance BCG’s protective efficacy.

Though first studies of MVA85A were promising, a recent phase II clinical trial revealed that the vaccine candidate did not offer extra protection against TB in South African infants who had already received the BCG vaccine.

The Jenner Institute is investigating a number of options to see if the immune response generated by MVA85A can be improved.

The Jenner Institute identified IMX313 as one of the best vaccine technologies to enhance immune responses in a comparison study funded by a grant from the Foundation for the National Institutes of Health through the Grand Challenges in Global Health initiative. It is now starting to evaluate it in humans in combination with MVA85A.

“Following a number of successes with IMX313 in preclinical trials, we are really pleased to have reached this milestone: the first administration of IMX313 in humans,” explains Dr. Fergal Hill, chief scientific officer of Imaxio. “We believe strongly that this will confirm fully that IMX313 is a real solution for developing more effective human vaccines and for addressing major infectious diseases.”

“We are keen to find out whether this novel vaccine candidate will pave the way for new successes in addressing tuberculosis,” said Prof. Helen McShane, tuberculosis program leader and professor of vaccinology at the Jenner Institute at Oxford University. “We think IMX313 may be a key component to help MVA85A show even greater potency in humans.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Imaxio Signs an Option for a License Agreement with DKFZ
Imaxio’s pro-immunogenic technology will be tested to enhance the efficacy of a candidate vaccine for the human papillomavirus.
Friday, October 17, 2014
Imaxio Announces the First Human Clinical Trial Using its Pro-Immunogenic Technology IMX313, in Tuberculosis
IMX313 has been administrated for the first time in humans as part of a tuberculosis vaccine phase I clinical trial.
Monday, September 16, 2013
Bellerophon Project Awarded EUR 5.5 Million by EU to Develop Staphylococcus Aureus Vaccine
A consortium has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.
Wednesday, July 03, 2013
Bellerophon Project Awarded EUR 5.5 Million by EU to Develop S. aureus Vaccine
A consortium comprising Imaxio, the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.
Tuesday, July 02, 2013
Imaxio Acquires Orphan Drug Indicated for a Congenital Metabolic Disease
This acquisition strengthens Imaxio’s pharmaceutical range, which now includes two products sold in France and will finance the development of its vaccine candidates.
Tuesday, January 22, 2013
Imaxio Signs an Option for a License Agreement with Merial
This option agreement confirms the potential of Imaxio’s antigen re-engineering technology to improve human and animal health vaccines.
Tuesday, December 18, 2012
Imaxio Boosts Genomics Capacity with New Automated Equipment
Investment means larger scale, faster high throughput sequencing for Imaxio customers.
Friday, June 29, 2012
Imaxio Closes EUR 2.9 Million Funding Round
Funding will enable the clinical development of its IMX313 carrier protein platform for vaccines, and update the marketing authorization application it filed in France.
Wednesday, April 18, 2012
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos